Cetuximab in combination with chemoradiotherapy in the treatment of recurrent and/or metastatic nasopharyngeal carcinoma. Issue 1 (January 2016)

• Record Type: Journal Article
• Authors: Xu, Tingting; Ou, Xiaomin; Shen, Chunying; Hu, Chaosu
• Is Part Of: Anti-cancer drugs. Volume 27:Issue 1(2016)
• Publication Date: 2016-01
• Subjects: cetuximab -- chemoradiotherapy -- nasopharyngeal carcinoma -- recurrent and/or metastatic; Antineoplastic agents -- Periodicals; Cancer -- Chemotherapy -- Periodicals; Antineoplastic Agents -- therapeutic use -- Periodicals; Drug Therapy -- Periodicals; 616.994061
• DOI: 10.1097/CAD.0000000000000294
• Languages: English
• ISSNs: 0959-4973

Abstract

Abstract : The aim of the study was to assess the efficacy and toxicity of cetuximab in the combined treatment for patients with recurrent and/or metastatic nasopharyngeal carcinoma (R/M NPC). Between March 2007 and November 2011, a total of 30 R/M NPC patients treated with comprehensive therapy including cetuximab were retrospectively enrolled. Intensity-modulated radiation therapy was delivered in recurrent disease with a median dose of 60 Gy. Chemotherapy regimens included TP/TPF (docetaxel 60–75 mg/m 2 d1+DDP 25 mg/m 2 d1–3±5-FU 500 mg/m 2 /day with 120-h infusion), GP (gemcitabine 1.0 g/m 2 d1, d8+DDP 25 mg/m 2 d1–3), and PC (paclitaxel 60 mg/m 2 /week d1+carboplatin AUC 2/week d1). Acute and late toxicities were documented by the radiation oncologists. The median age of the patients was 44 years (range 26–62). A total of 21 patients (70%) achieved response (CR+PR). The median survival time, time to progression, and 2-year overall survival were 23.6, 12.2 months, and 53.3%, respectively. Cetuximab appears to be effective and well tolerated when combined with chemoradiation therapy for the treatment of R/M NPC.